甘利欣联合胸腺肽、华蟾素治疗慢性乙型肝炎疗效观察

Analysis of combined therapy of diammenium glycyrrhizinate thymus peptide and cinobufotalin for the treatment of chronic hepatitis B

目的 :观察甘利欣联合胸腺肽及华蟾素对慢性乙型肝炎 (CHB)的疗效。方法 :将 196例CHB病人随机分为 4组 ,A组 5 6例采用甘利欣联合胸腺肽与华蟾素 ;B组 5 0例用甘利欣联用胸腺肽 ;C组 4 6例用甘利欣联用华蟾素 ;D组 4 4例用门冬氨酸钾镁和五酯胶囊。疗程均为 3个月。结果 :治疗结束时 4组ALT复常率分别为 92 .8%、78%、76 %、5 2 .2 %。SB复常率为 87.5 %、70 %、6 9.5 %、4 5 .4 %。HBeAg转阴率 39.2 %、30 %、30 .4 %、9%。HBV—DNA转阴率 4 1%、2 8%、2 8.2 %、6 .8%。停药后随访一年 ,ALT复常率分别为 85 .7%、6 6 %、6 5 .2 %、4 0 .9%。SB复常率分别为 83.9%、6 4%、6 3%、36 .3%。A组与D组比较P <0 .0 1,A组分别与B组及C组比较P <0 .0 5。HBeAg转阴率 37.5 %、2 6 %、2 6 %、6 .8%。HBV—DNA转阴率 37.5 %、2 4 %、2 3.9%、6 .8%。A组与D组比较P <0 .0 0 1,A组分别与B组及C组比较P >0 .0 5。结论 :三种药联合治疗慢性乙型肝炎可取得较好的远期疗效。

Objective: To evaluate the therapeutic results of the combtned regimen of diammonium glycyrrhiztnate, thymus peptide and cinobufotalin for treating chronic hepatitis B (CHB) . Methods: 196 cases of patient with chronic heptitis B were divided into 4 groups at random. The group A(56 cases) were given took diammonium glycyrrhtzinate, Thymos and cinobufotaltn. The group B (50 cases) took diammonium glycyrrhizinate and thymus. The groups C (46 ceses) took diammonium and cinobufotalin. The group D(44 cases) took potassium and Wuzhi capsules. The therapeutic course were 3 months. Results: By thd end of therapy, in group A, B, C and D, the rates of ALT turning to recover were 92.8%, 78%, 76% and 52.2% respectively, and that of SB 87.5%, 70%, 69.5% and 45.4% respectively. The rates of HBeAg turning to negative were 39.2%, 30%, 30.4% and 9% respectively, and that of HBV-DNA 41%, 28%, 28.2% and 6.8% respectively. Following up for one year, the rates of ALT turning to recover were 85.7%, 66%, 65.2% and 40.9% respectively, and that of SB 83.9%, 64%,63% and 36.3% respectively. Significant differences existed Between group A and D (P<0.01). Differences were also significant between group A and B, group A and C (P<0. 05). The rates of HBeAg turning to normality were 37.5%, 26%, 26% and 6.8% respectively, that of HBV-DNA 37.5%, 24%, 23.9% and 6.8% respectively, The rates of HBeAg and HBV-DNA of group A tnrning to negative were significant higher than that of group D(P<O.OOI) . There were no differences between group A and B, and group A and C(p>0.05). Conclusion: The combintion of the three durps for treating chronic hepatitis B has long term therapeutic effectiveness.